Watch More Highlights
Kelly Valla, PharmD, BCOP, of Winship Cancer Institute of Emory University, discusses mantle cell lymphoma and what advanced practitioners should know about improving outcomes in relapsed and refractory disease with BTK inhibitors such as treatment with pirobrutinib; other new agents such as parsaclisib, a PI3K delta inhibitor, and the bispecific agent epcoritamab; and CAR T-cell therapy. She also relays some clinical pearls on toxicity management (including financial toxicity) and supportive care.